From: Management of febrile urinary tract infection among spinal cord injured patients
Treatment duration (days) | <10 d | 10-15 d | >15 d | Total | P value |
---|---|---|---|---|---|
Number of febrile UTIa | 28 | 35 | 49 | 112 | |
Patient characteristics | |||||
Sex (women/men) | 12/16 | 11/24 | 9/40 | 32/80 | 0.2453 |
Age: mean year (SD) | 49.6 (20.1) | 46.5 (24.7) | 31 (19.7) | 38.4 (11.7) | 0.1443 |
Fever: mean °C (SD) | 38.6 (0.33) | 38.9 (0.76) | 39.07 (0.78) | 38.8 (0.6) | 0.5469 |
Neurological deficit N (%) | |||||
Paraplegia | 18 (64) | 20 (57) | 27 (55) | 65 (58) | 0.2604 |
Tetraplegia | 5 (18) | 2 (6) | 13 (27) | 20 (18) | 0.5205 |
Multiple sclerosis | 4 (14) | 6 (17) | 6 (12) | 16(14) | 0.9299 |
Brain injury | 1 (4) | 7 (20) | 3 (6) | 11(10) | 0.1042 |
Voiding management N (%) | |||||
Intermittent cathererization | 14 (50) | 13 (37.1) | 30 (62) | 57 (51) | 0.4564 |
Indwelling catheter | 2 (7) | 4 (11) | 6 (12) | 12 (10) | 0.9899 |
Reflex voiding | 7 (25) | 8 (23) | 7 (14) | 22 (19) | 0.8349 |
Urinary diversion | 2 (7) | 6 (17) | 3 (6) | 11 (10) | |
Others | 3 (11) | 4 (11) | 3 (6) | 10 (10) | |
Biological variables | |||||
Leukocyte count: median/L (SD) | 12. 9 (5.5) | 13 (6.9) | 12 (5.7) | 12.6 (6) | 0.4426 |
CRP mean mg/l (SD) | 140 (84) | 139 (89) | 122(90) | 121 (84) | 0.9953 |
Positive blood culture N (%) | 3 (10) | 5 (14) | 9 (18) | 17 (15) | 0.5246 |
Microorganism sample N (%) | |||||
E coli | 17 (53) | 16 (37.2) | 22 (33) | 55 (49) | |
Pseudomonas aeruginosa | 6 (18.7) | 6 (13.9) | 7 (10.6) | 19 (13.5) | |
Enterococcus | 4 (12.5) | 7 (16.2) | 8 (12) | 19 (13.5) | |
Klebsiella | 2 (6.25) | 4 (9.3) | 8 (12) | 14 (10) | |
Proteus | 1 (3.12) | 3 (7) | 4 (6) | 8(5.6) | |
Others | 2 (6.43) | 7 (16.4) | 17 (26.4)) | 26 (18.4) | |
Antibiotic treatment | |||||
Mean treatment duration (SD) | 7.9 (2.3) | 13.4 (1.9) | 27.3 (9.8) | 18.1 (10.7) | 0.0250 |
Mean parenteral treatment duration (median, SD) | 8 (8, ±2.2) | 6.8 (5, ±5.33) | 11.2 (7, ±10.6) | 8.2 (6, ±8.3) | |
Dual therapy N (%) | 17 (61) | 18 (52) | 34 (70) | 69 (62) | 0.9669 |
Antibiotic treatment N (%) | |||||
Third generation cephalosporin | 16 (33) | 19 (26.3) | 32 (32) | 67 (30.6) | |
Aminoglycosides | 12 (25) | 18 (25) | 21 (21) | 51 (23.2) | |
Fluoroquinolones | 6 (12.5) | 14 (19.4) | 16 (16) | 36 (16.4) | |
Penicillin | 9 (18.8) | 12 (16.7) | 14 (14) | 35 (16) | |
Carbapenem | 4 (8.3) | 5 (6.9) | 11 (11) | 20 (9.1) | |
Colimycin | 1 (2) | 2 (2.8) | 2 (2) | 5 (2.3) | |
Cotrimoxazole | 0 | 0 | 3 (3) | 3 (1.4) | |
Fosfomycin | 0 | 2 (2.8) | 0 | 2 (1) | |
Outcome (1 month) | |||||
Cure N (%) | 20 (71.4) | 19 (54.2) | 28 (57.1) | 67 (60.0) | 0.3979 |
Failure N (%) including: | 6 (21.6) | 10 (28.5) | 15 (30.8) | 31 (27.5) | |
Persistence of symptoms | 5 (17.8) | 9 (25.7) | 12 (24.4) | 26 (23.2) | |
Death related to UTI | 1 (3.5) | 1 (3) | 3 (6.1) | 5 (4.4) | |
Patients who could not be evaluated N (%)b | 2 (7.1) | 6 (17.1) | 6 (12.2) | 14 (12.5) | |
Requiring another antibiotic treatment for concomitant infection | 0 | 1 | 4 | 5 | |
Lost to follow up | 1 | 1 | 1 | 3 | |
Death unrelated to UTI | 1 | 4 | 1 | 6 | |
Negative urine culture (D30) N (%) | 17 (60.7) | 15 (42.8) | 21 (42.8) | 53 (47.3) | 0.635 |